Acute Antibody-mediated Rejection 1 Week After Lung Transplantation Successfully Treated With Eculizumab, Intravenous Immunoglobulins, and Rituximab

Transplantation. 2018 Jun;102(6):e301-e303. doi: 10.1097/TP.0000000000002165.

Authors

Yannick D Muller¹, John-David Aubert^{1

2}, Julien Vionnet¹, Samuel Rotman³, Salima Sadallah⁴, Vincent Aubert⁴, Manuel Pascual¹

Affiliations

¹ Transplantation Center, Lausanne University Hospital, University of Lausanne, Switzerland.
² Service of Pneumology, Lausanne University Hospital, University of Lausanne, Switzerland.
³ Service of Clinical Pathology, Lausanne University Hospital, University of Lausanne, Switzerland.
⁴ Service of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, Switzerland.

PMID: 29521880
DOI: 10.1097/TP.0000000000002165

No abstract available

Publication types

Case Reports
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use*
Drug Therapy, Combination
Female
Graft Rejection / diagnosis
Graft Rejection / drug therapy*
Graft Rejection / immunology
Graft Survival / drug effects*
Humans
Immunoglobulins, Intravenous / therapeutic use*
Immunosuppressive Agents / therapeutic use*
Isoantibodies / immunology*
Lung Transplantation / adverse effects*
Middle Aged
Rituximab / therapeutic use*
Time Factors
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
Immunoglobulins, Intravenous
Immunosuppressive Agents
Isoantibodies
Rituximab
eculizumab